FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Epirubicin Hydrochloride Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Cipla Limited (New 07/17/2019)

Company Contact Information:

Presentation Posting Date Related Information
2 mg/1 mL (NDCs 25021-203-25 and 59923-701-25) 07/17/2019 Anticipated unavailability of product is September 2019.

Teva Pharmaceuticals (New 07/17/2019)

Company Contact Information:

Presentation Posting Date Related Information
2 mg/1 mL (NDCs 45963-608-60 and 45963-608-68) 07/17/2019 This product discontinuation is a business related decision. Anticipated discontinuance time is first quarter of the year 2020.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English